Tg511-11-01: A Phase 1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to subjects at the time of Resection for Recurrent High Grade Glioma and Followed by Treatment with Toca FC, Extended-Release 5-FC

Cancer - Brain
  1. Is the subject between 18 and 80 years old inclusive?
  2. Has the subject undergone at least one prior surgical gross-total or subtotal tumor resection and a course of postoperative radiation therapy with concurrent temozolomide?
  3. Does the subject have a single tumor recurrence/progression that is < or = 6 cm in its greatest dimension?
Tiffany Pearce